Tejal Somvanshi
New Phase 3 trial data published in TRIUMPH-2 PubMed record this week shows Eli Lilly's retatrutide helped adults with both type 2 diabetes and obesity lose up to 19.8% of their body weight over 80 weeks — a result that closes a gap that has frustrated physicians treating this specific patient group for years. This update covers the TRIUMPH-2 results, which are distinct from earlier retatrutide data published in October 2026.
The TRIUMPH-2 Phase 3 trial enrolled 1,152 adults with obesity and type 2 diabetes across 80 weeks of subcutaneous weekly injections. At the highest dose (12mg), participants lost up to 19.8% of body weight. The trial also showed significant reductions in HbA1c — a key marker of long-term blood sugar control. Adverse events included treatment discontinuation in 8% of patients at the 12mg dose and 12% at 9mg, with a unique side effect called dysesthesia — mild burning or skin sensitivity sensations — reported in 4% to 7% of participants. The data was published in The Lancet; Eli Lilly has not yet filed a New Drug Application with the FDA for retatrutide.
Adults living with type 2 diabetes and clinical obesity, along with their endocrinologists, face a transformative therapeutic development as retatrutide demonstrates unprecedented dual glycemic control and weight reduction in Phase 3 trials. Patients struggling with plateaued weight loss on existing single or dual-agonist therapies should discuss forthcoming triple-hormone clinical data with their physicians. Individuals must evaluate potential gastrointestinal tolerability, injection titration schedules, and clinical trial availability as regulatory filings progress toward commercial review.
Why Diabetic Patients Have Historically Lost Less Weight on GLP-1 Drugs
This is the central clinical question the TRIUMPH-2 data addresses. Patients with type 2 diabetes consistently achieve 30% to 50% less weight reduction on GLP-1 receptor agonists — drugs like semaglutide (Ozempic, Wegovy) — compared to people without diabetes. The reason involves altered insulin resistance and compensatory metabolic adaptations that blunt the energy expenditure signal these drugs normally trigger.
Retatrutide is a triple agonist: it activates receptors for GIP, GLP-1, and glucagon simultaneously. The glucagon receptor component is the clinically relevant addition for diabetic patients. Glucagon receptor activation drives energy expenditure and suppresses appetite through a pathway distinct from the incretin signaling that insulin resistance partially blocks. In TRIUMPH-2, that triple-pathway engagement appears to override the metabolic brake that type 2 diabetes imposes, delivering weight loss outcomes that approach what non-diabetic trial participants have shown in earlier studies. FDA approval and evidence on Zepbound.
Unlike earlier dual agonists — tirzepatide (Zepbound/Mounjaro) — where weight loss typically plateaus between weeks 52 and 64, retatrutide's weight-loss trajectory in TRIUMPH-2 had not reached a complete plateau by week 80. That sustained trajectory suggests ongoing metabolic effects rather than a ceiling effect, though the long-term outcome beyond 80 weeks has not yet been established.
The comparison point matters for patients considering switching: tirzepatide produces approximately 15% weight loss in diabetic populations; retatrutide's near-20% result in the same population represents a meaningful clinical difference, not just a statistical one. Read a summary of current FDA-approved weight-loss medications and their efficacy comparisons.
How does retatrutide differ from Ozempic and Zepbound?
Eli Lilly's Phase 3 TRIUMPH-2 trial demonstrated that retatrutide, a triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways simultaneously, helped adults with type 2 diabetes and obesity lose up to nearly 20% of their body weight over 80 weeks. The glucagon receptor activation is the key addition beyond existing dual-agonist drugs, enabling weight loss in a patient population that typically responds less strongly to GLP-1 drugs alone.
Eli Lilly has not announced a regulatory filing date for retatrutide. An FDA New Drug Application submission would be the next milestone; check back for updates as Lilly's regulatory timeline is disclosed.
